World

Revolution Medicines secures FDA approval for pancreatic cancer drug

Revolution Medicines has received approval from U.S. regulators for daraxonrasib, a new treatment targeting pancreatic cancer's underlying causes.

27 August 2026Tagblick Newsdesk

AI-generatedWritten by an AI system, editorially responsible — how we work

Archive photo: Revolution Medicines secures FDA approval for pancreatic cancer drug — Archive photoPhoto: Jovan.gec · Wikimedia Commons · CC BY-SA 4.0

Revolution Medicines, a U.S. biotechnology company, has gained regulatory approval for its drug daraxonrasib in the United States. This new treatment is aimed at addressing one of the key molecular causes of pancreatic cancer, a disease known for its high mortality rate.

The drug has been identified as the first of its kind to specifically target these molecular factors associated with pancreatic cancer. According to various reports, daraxonrasib has shown promise in clinical studies, indicating its potential to change treatment protocols for this type of cancer.

Studies cited by CBS News reveal that patients using daraxonrasib had a median survival of 13.2 months, compared to 6.7 months for those receiving traditional chemotherapy. This information underscores the drug's potential effectiveness in extending patient life expectancy.

Health officials in the U.S. have termed the approval of daraxonrasib a landmark move in the fight against pancreatic cancer. NPR reported that the drug operates by blocking a specific protein that promotes tumor growth, offering a novel approach to treatment.

The approval process underscores a growing interest in developing targeted therapies for pancreatic cancer, a field that has seen limited advancements in recent years. The approval has been met with positivity within the medical community, emphasizing the need for innovative treatments.

Experts have expressed cautious optimism regarding the drug's ability to significantly impact patient outcomes, acknowledging the challenges that still remain in combating one of the world's deadliest cancers. The approval marks a significant step in potential therapies available for patients.

This item was written by an AI system on the basis of the headlines and short teasers of the independently operating newsrooms named below. We disclose this under Art. 50(4), second subparagraph, of Regulation (EU) 2024/1689 (AI Act). Before publication we check origin and verifiability — anything that appears in only one place is not published — as well as language, substance and legally sensitive content. No separate substantive review of each individual item by a natural person takes place; we therefore do not rely on the exemption in Art. 50(4), second subparagraph, of the AI Act. Editorial responsibility for this publication rests with the person named in the imprint (§ 18 Abs. 2 MStV). Please report errors to [email protected] — we will correct or remove the item. Full reports are available from the sources listed.